A prescription drug used for treating patients with advanced kidney cancer could slow the disease progression in liver cancer patients as well, scientists said Monday. Presenting the findings during the 43rd annual meeting of the American Society of Clinical Oncology, researchers suggested that the oral tablets containing Sorafenib could provide a potential solution for the treatment of patients with fatal liver caner.
Sorafenib is an active ingredient in Nexavar tablets, co-developed by Bayer Pharmaceuticals Corp. and Onyx Pharmaceuticals Inc., used to treat patients with advanced kidney cancer
